Advertisement
Advertisement
VRDN
Viridian Therapeutics, Inc. Common Stock
31.25
USDSponsored
+0.39
+1.26%
Nov 11, 16:00 UTC -5
Closed
Pre-Market
30.30
-0.95
-3.05%
Viridian Therapeutics, Inc. Common Stock (VRDN) Earnings
VRDN Earnings Reports
Positive Surprise Ratio
VRDN beat 25 of 42 last estimates.
60%
Next Report
Date of Next Report
Feb 24, 2027
Estimate for Q4 26 (Revenue/ EPS)
$46.26M
/-$0.76
Implied change from Q3 26 (Revenue/ EPS)
+79.63%
/-6.17%
Implied change from Q4 25 (Revenue/ EPS)
+34945.11%
/-29.63%
Viridian Therapeutics, Inc. Common Stock earnings per share and revenue
On Nov 04, 2026, VRDN reported earnings of -0.81 USD per share (EPS) for Q3 26, beating the estimate of -0.98 USD, resulting in a 18.04% surprise. Revenue reached 25.75 million, compared to an expected 5.19 million, with a 396.64% difference. The market reacted with a +15.53% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 9 analysts forecast an EPS of -0.76 USD, with revenue projected to reach 46.26 million USD, implying an decrease of -6.17% EPS, and increase of 79.63% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alvotech Ordinary Shares
Report Date
Nov 11, 2026 For Q3 26
Estimate
-$0.04
Actual
-$0.03
Surprise
+36.97%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Opus Genetics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.18
Surprise
-19.68%
Alpha Cognition Inc. Common Stock
Report Date
Nov 11, 2026 For Q3 26
Estimate
-$0.33
Actual
-$0.28
Surprise
+17.31%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
MiNK Therapeutics, Inc. Common Stock
Report Date
Nov 11, 2026 For Q3 26
Estimate
-$0.51
Actual
-$0.50
Surprise
+1.96%
iBio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q1 27
Estimate
-$0.07
Actual
-$0.05
Surprise
+33.16%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
CalciMedica, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$1.30
Actual
-$0.72
Surprise
+44.64%
FAQ
What were Viridian Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Viridian Therapeutics, Inc. Common Stock reported EPS of -$0.81, beating estimates by 18.04%, and revenue of $25.75M, 396.64% above expectations.
How did the market react to Viridian Therapeutics, Inc. Common Stock's Q3 2026 earnings?
The stock price moved up 15.53%, changed from $25.15 before the earnings release to $29.05 the day after.
When is Viridian Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 24, 2027.
What are the forecasts for Viridian Therapeutics, Inc. Common Stock's next earnings report?
Based on 9
analysts, Viridian Therapeutics, Inc. Common Stock is expected to report EPS of -$0.76 and revenue of $46.26M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.